Abstract
The number of confirmed cases of coronavirus disease 2019 (COVID-19) worldwide exceeded 750 million as of February 2023 [1], leaving an estimated 65 million individuals experiencing post-acute sequelae of COVID-19 or ‘long COVID’, or a modelled estimate of 6.2% of individuals experiencing long COVID symptoms three months after symptomatic SARS-CoV-2 infection [2, 3]. Early in the pandemic, we proposed the Post-COVID-19 Functional Status (PCFS) scale in the European Respiratory Journal, which resulted from a slight adaptation of the Post-Venous thromboembolism Functional Status (PVFS) scale developed in 2019 [4–6]. The PCFS scale is designed to monitor functional recovery and identify patients with incomplete or poor recovery after COVID-19 in research and clinical practice.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
